An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1) [0.03%]
派姆单抗联合曲妥珠单抗、氟尿嘧啶和铂类化疗治疗HER2阳性PD-L1(CPS≥1)表达胃或食管胃交界部腺癌的疗效评价
Kyosuke Seguchi,Akihito Kawazoe,Izuma Nakayama et al.
Kyosuke Seguchi et al.
Introduction: Despite the introduction of several novel agents, survival for patients with metastatic gastric or gastroesophageal junction adenocarcinoma remains limited. In human epidermal growth factor receptor 2 (HER-2...
Body composition and physical activity as predictors of immune-related adverse events in patients undergoing cancer immunotherapy: a systematic review [0.03%]
身体组成和体力活动对接受癌症免疫治疗患者的免疫相关不良事件的预测作用：系统综述
Len De Nys,Güleser Güney,Frederique I J Grootjans et al.
Len De Nys et al.
Introduction: Host factors may affect immune-related adverse events (irAE) during immune checkpoint inhibitor (ICI) therapy. We systematically reviewed studies on body composition (BMI, CT/DXA-defined sarcopenia, sarcopen...
Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas [0.03%]
雷佐沙喃用作治疗软组织肉瘤的放射增敏剂的研究
John Rothman
John Rothman
Introduction: Razoxane, discovered in the 1960s, was evaluated as a topoisomerase II inhibitor to treat cancer. Cancer therapeutic models of the mid-1900's were based on the following three assumptions: treatment agents s...
Impact of health-related social needs on mortality risk in cancer survivors: evidence from 1999-2018 NHANES [0.03%]
美国NHANES 1999-2018年数据中癌症幸存者健康相关社会需求对死亡风险的影响
Pingping Xu,Zhengchuan Niu,Donghao Xu et al.
Pingping Xu et al.
Background: Cancer survivors experience disproportionate burdens of health-related social needs (HRSNs), yet the mortality implications of cumulative HRSN burden remain poorly characterized. ...
From fecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy: how far down the road are we? [0.03%]
从粪菌移植到精准干预改善免疫检查点抑制治疗：我们走得多远了？
Madieke Kleinhans,Anouk Lissen,Lucy Hewitson et al.
Madieke Kleinhans et al.
Introduction: The outcome of immune checkpoint inhibition (ICI) therapy of cancer appears to be influenced by the gut microbiota composition of the patient. Microbiome-based therapy by fecal microbiota transplantation (FM...
Management of tenosynovial giant cell tumor: approved and investigational therapies [0.03%]
滑膜巨细胞肿瘤的治疗：已获批及在研药物
Alexander P Conway,Andrew Lim,Brian C Schulte et al.
Alexander P Conway et al.
Introduction: Tenosynovial giant cell tumor (TGCT) is a rare, benign neoplasm driven by overexpression of colony-stimulating factor 1 (CSF-1), which recruits CSF-1 receptor (CSF-1 R)-bearing macrophages and other inflamma...
REGULATORY LANDSCAPE FOR CAR-T THERAPY DEVELOPMENT IN THE BRAZILIAN CONTEXT [0.03%]
巴西CAR-T治疗研发的监管环境
Felipe Pantoja Mesquita,Marília Silveira Maia,Pedro Filho Noronha Souza et al.
Felipe Pantoja Mesquita et al.
Introduction: Chimeric antigen receptor T (CAR-T) therapy represents a significant advance in the treatment of hematologic malignancies, yet its global implementation remains limited by regulatory, logistical, and manufac...
An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer [0.03%]
taletrectinib治疗ROS1阳性非小细胞肺癌的疗效评估
Ravand Samaeekia,Zhaohui Arter,Misako Nagasaka
Ravand Samaeekia
Introduction: ROS1 fusion - positive non-small cell lung cancer (NSCLC) represents a rare but clinically important subset, occurring in 1-2% of patients and often associated with younger, never-smoker populations. Current...
Artificial intelligence in bladder cancer management: a narrative review of diagnostic and surgical advances and current limitations [0.03%]
人工智能在膀胱癌管理中的应用：诊断和外科手术进展及当前局限性的叙事性综述
Gaetano Salzano,Alessio Digiacomo,Guglielmo Dello Stritto et al.
Gaetano Salzano et al.
Introduction: Bladder cancer (BC) is associated with high recurrence and progression rates that require intensive surveillance. In this context, Artificial Intelligence (AI) offers promising tools to enhance diagnostic, p...
Cancer genome profiling in sarcomas: current status and future perspectives in Japan [0.03%]
日本软组织肉瘤的基因组分析：现状与未来展望
Tatsusnori Shimoi,Shosuke Kita,Kan Yonemori
Tatsusnori Shimoi
Introduction: Sarcomas are rare, molecularly diverse malignancies that challenge accurate diagnosis and effective therapy. Japan has implemented nationwide comprehensive cancer genomic profiling (CGP) since 2019, creating...